• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Clavister: Improving margins backed by cost control - ABG

CLAVThird party research07.11.2025, 10.02

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Q3: EBITDA of SEK 13m and a margin of 25%* We cut EBITDA by 5-2% for '26e-'27e* Currently trading at 37x EV/EBITDACost control and improving cross salesClavister reported sales of SEK 50m, corresponding to 15% y-o-y growth (17% organic, -1% FX), in line with the pre-announced figures. Growth was mainly driven by previously won defence orders, where sales increased by ~100% y-o-y this quarter, representing ~25% of total sales. Sales growth in the civilian business was held back somewhat by timing effects, but ARR increased 9%, demonstrating a solid underlying trend and steady demand. EBITDA amounted to SEK 13m, corresponding to a 25% margin – the highest to date – supported by firm cost control and stronger cross sales efforts.Postponed projects to set in 2026We cut sales by 2-1% for '26e-'27e, mainly reflecting delayed orders. We expect Q4 organic growth of ~10%, driven by postponed deliveries. We also cut EBITDA by 5-2% for the same period, with EBITDA now expected at SEK 69-94m, representing margins of ~25-30%. Q3 was seasonally softer and affected by distributors postponing purchasing decisions, which we expect to be realised during H1'26e. We see this as a timing issue rather than a structural slowdown, and expect momentum to normalise as deliveries ramp up.Improving fundamentalsClavister is now trading at 20-15x EV/EBITDA for '26e-'27e on our revised estimates. We believe the company is well-positioned to reach positive EBIT on the full year in 2026, supported by cost efficiencies and operating leverage.